Final programme - eshre 2013

P-557 Altered sensitivity rather than decreased amounts of FSH (FSHR) and androgen receptors (AR) ingranulosa cells might be beneath the development of diminished ovarian responseC. Díaz-García, M. Monterde, A. Marzal, O. Vega, J.M. Rubio, R. Gómez, A. Pellicer (Reproductive Medicine)P-558 superovulation influences epab and pabpc1 gene expressions in mouse oocytes and earlypreimplantation embryosS. Ozturk, B. Sozen, A. Yaba-Ucar, D. Mutlu, N. Demir (Turkey)P-559 a randomised, double-blind, active-controlled, multiple-dose trial investigating the pharmacokineticsand pharmacodynamics of a novel recombinant fsH (FE 999049) derived from a human cell lineH. Olsson, R. Sandström, L. Grundemar (Denmark)P-560 Blastocyst transfer as a clinical strategy to overcome progesterone elevation on the day of hCGadministrationE. Papaleo, L. Corti, E. Rabellotti, V.S. Vanni, M. Potenza, M. Molgora, P. Viganò, M. Candiani (Italy)P-562 different pharmacokinetic properties between a novel recombinant fsH (FE 999049) derived froma human cell line and follitropin alfaR. Sandström, H. Olsson, L. Grundemar (Denmark)P-563 the evaluation of AMH and AMHR2 genes polymorphisms in infertile women and the correlation withAMH, fsH and estradiol serum levels and assisted reproduction outcomesP. Peluso, C.M. Trevisan, E.B. Cordts, V. Cavalcanti, D.M. Christofolini, F.A. Fonseca, C.P. Barbosa,B. Bianco (Brazil)P-564 premature luteinization in IVF or ICSI cycles using GnRH antagonists for pituitary downregulationP. Bakas, N. Vlahos, D. Hassiakos, D. Tzanakaki, O. Gregoriou, A. Liapis, G. Creatsas (Greece)P-565 impact of FMR1 mutation on follicle responsiveness to exogenous fsH as measured by the FollicleOutput RaTe (fort)E. Adda-Herzog, J. Steffann, S. Sebag-Peyrelevade, M. Poulain, A. Benachi, R. Fanchin (France)P-566 does delayed endometrial shedding post OC pretreatment increase pregnancy rates in womenundergoing COS with rfsH in a GnRH antagonist regimenK. Gordon, D. Zhang, A. Nyboe Andersen (U.S.A.)P-567 decreased estradiol level after hcg administration can be used as a predictor for poor ivf outcomeF. Aybar, S. Temel, S. Kahraman (Turkey)P-568 simultaneous initiation of GnRH antagonist co-treatment and recfsH for ovarian hyperstimulation in IVFdoes not affect clinical outcome: a randomized controlled trialO. Hamdine, N.S. Macklon, M.J.C. Eijkemans, J.S. Laven, B.J. Cohlen, A. Verhoeff, P.A. van Dop,R.E. Bernardus, C.B. Lambalk, G.J.E. Oosterhuis, C.A.G. Holleboom, G.C. van den Dool-Maasland,H.J. Verburg, P.F.M. van der Heijden, A. Blankhart, B.C.J.M. Fauser, F.J. Broekmans (The Netherlands)P-569 a comparative study of antral follicle count with fsH and AMH in an IVF programmeJ. Bhattacharya, A. Mitra, G.B. Dutta, A. Kundu, M. Bhattacharya, S. Kundu (India)P-570 Comparative analysis of two widely-used immunoassays for the measurement of serum AMH in womenP. Pigny, A. Dassonneville, S. Catteau-Jonard, C. Decanter, D. Dewailly (France)180